Exhibit 99.1
FOR IMMEDIATE RELEASE
Emdeon Reports Second Quarter 2014 Results
| • | Revenue of $336.2 million for Second Quarter 2014 |
| • | Adjusted EBITDA of $90.3 million for Second Quarter 2014 |
NASHVILLE, Tenn. (August 7, 2014) – Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced financial results for the second quarter ended June 30, 2014 as summarized below:
| (In millions) | 2Q 2014 | 2Q 2013 | % Change | |||||||||
| Revenue |
$ | 336.2 | $ | 305.3 | 10.1 | % | ||||||
| Net Loss |
$ | 59.5 | $ | 28.3 | -110.6 | % | ||||||
| Non-GAAP Adjusted EBITDA |
$ | 90.3 | $ | 77.2 | 17.1 | % | ||||||
“We are pleased with the 10.1% increase in revenue as compared to the prior year quarter and the acceleration of our revenue growth from the first quarter. Combined with the 17.1% increase in Adjusted EBITDA over the prior year period, our quarterly financial results were strong. The revenue growth was due to ongoing increased sales of our solutions and transaction volume gains due to the increase in the number of insured lives of our customers and improved general economic conditions. During the second quarter, we continued to experience positive momentum throughout our business as evidenced by a robust pipeline and a continued substantial increase in new sales over the prior year quarter,” said Neil de Crescenzo, president and chief executive officer for Emdeon. “We are excited to expand our capabilities with the acquisition of Capario that closed in late July and brings a suite of innovative, cloud-based applications. Capario is expected to add to our Adjusted EBITDA in 2014 and further enhances our strategy and forward growth trajectory.”
Second quarter revenue was $336.2 million, an increase of 10.1%, compared to $305.3 million for the same period in 2013. This increase in revenue was primarily due to business growth. Net loss for the second quarter of 2014 was $59.5 million compared to $28.3 million for the same period in 2013. This increase in net loss was primarily due to a non-cash impairment charge related to the anticipated partial loss of a contract in Emdeon’s pharmacy services business.
Second quarter 2014 Non-GAAP Adjusted EBITDA increased 17.1% to $90.3 million, or 26.9% of revenue, from Non-GAAP Adjusted EBITDA of $77.2 million, or 25.3% of revenue, for the comparable period in 2013. This increase in Adjusted EBITDA and as a percentage of revenue as compared to the same period in 2013 is primarily due to business growth and productivity improvements throughout the business, partially offset by increased investments related to sales and product development initiatives.
On July 21, 2014, Emdeon completed the acquisition of Capario, Inc., an innovative company providing industry-leading, cloud-based healthcare technology solutions. The acquisition of Capario extends Emdeon’s ability to help healthcare providers get reimbursed quickly, accurately and cost-effectively.
A reconciliation of Emdeon’s financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis. An explanation of these non-GAAP measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
1
About Emdeon
Emdeon is a leading provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers, pharmacies and patients in the U.S. healthcare system. Emdeon’s offerings integrate and automate key business and administrative functions of its payer, provider and pharmacy customers throughout the patient encounter. Through the use of Emdeon’s comprehensive suite of solutions, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes. For more information, visit www.emdeon.com.
Forward-Looking Statements
Statements made in this press release that express Emdeon’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. Forward-looking statements may include information concerning Emdeon’s possible or assumed future results of operations, including descriptions of Emdeon’s revenues, profitability, outlook and overall business strategy. You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon’s operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon’s control. Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. Such factors related to Emdeon’s actual financial results or results of operations include: effects of competition, including competition from entities that are customers for certain of Emdeon’s solutions; Emdeon’s ability to maintain relationships with its customers and channel partners; Emdeon’s ability to effectively cross-sell its solutions to existing customers and to continue to generate revenue and maintain profitability by developing or acquiring and successfully deploying new or updated solutions; pricing pressures on Emdeon’s solutions; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and elsewhere in Emdeon’s Annual Report filed on Form 10-K for the year ended December 31, 2013, as well as other reports filed by Emdeon with the Securities and Exchange Commission.
You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
# # #
Contacts:
Investor Relations
Bob East
Westwicke Partners
443.213.0502
bob.east@westwicke.com or
Emdeon@westwicke.com
2
Emdeon Inc.
Condensed Consolidated Statements of Operations
(unaudited and amounts in thousands)
| Three Months | Three Months | Six Months | Six Months | |||||||||||||
| Ended | Ended | Ended | Ended | |||||||||||||
| June 30, | June 30, | June 30, | June 30, | |||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenue |
$ | 336,158 | $ | 305,283 | $ | 655,365 | $ | 604,642 | ||||||||
| Costs and expenses: |
||||||||||||||||
| Cost of operations (exclusive of depreciation andamortization below) |
201,398 | 188,026 | 395,538 | 371,449 | ||||||||||||
| Development and engineering |
7,380 | 7,626 | 16,616 | 15,324 | ||||||||||||
| Sales, marketing, general and administrative |
53,602 | 40,658 | 105,711 | 79,364 | ||||||||||||
| Depreciation and amortization |
46,630 | 43,946 | 93,093 | 90,762 | ||||||||||||
| Accretion |
4,844 | 7,459 | 4,768 | 11,599 | ||||||||||||
| Impairment of long-lived assets |
76,508 | 1,893 | 79,576 | 1,862 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating income |
(54,204 | ) | 15,675 | (39,937 | ) | 34,282 | ||||||||||
| Interest expense, net |
36,543 | 37,974 | 73,106 | 79,389 | ||||||||||||
| Loss on extinguishment of debt |
— | 23,160 | — | 23,160 | ||||||||||||
| Contingent consideration |
(290 | ) | — | 1,670 | — | |||||||||||
| Other |
(3,971 | ) | — | (3,971 | ) | — | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) before income tax provision (benefit) |
(86,486 | ) | (45,459 | ) | (110,742 | ) | (68,267 | ) | ||||||||
| Income tax provision (benefit) |
(26,959 | ) | (17,191 | ) | (48,226 | ) | (26,547 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | (59,527 | ) | $ | (28,268 | ) | $ | (62,516 | ) | $ | (41,720 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
3
Emdeon Inc.
Condensed Consolidated Balance Sheets
(unaudited and amounts in thousands, except share and per share amounts)
| June 30, | December 31, | |||||||
| 2014 | 2013 | |||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 71,177 | $ | 76,538 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $4,325 and $3,856 at June 30, 2014 and December 31, 2013, respectively |
239,895 | 214,247 | ||||||
| Deferred income tax assets |
17,809 | 6,317 | ||||||
| Prepaid expenses and other current assets |
33,474 | 27,019 | ||||||
|
|
|
|
|
|||||
| Total current assets |
362,355 | 324,121 | ||||||
| Property and equipment, net |
242,188 | 269,470 | ||||||
| Goodwill |
1,508,593 | 1,502,434 | ||||||
| Intangible assets, net |
1,513,894 | 1,632,688 | ||||||
| Other assets, net |
20,845 | 19,169 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 3,647,875 | $ | 3,747,882 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 9,245 | $ | 8,367 | ||||
| Accrued expenses |
126,687 | 131,149 | ||||||
| Deferred revenues |
10,001 | 10,881 | ||||||
| Current portion of long-term debt |
23,565 | 31,330 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
169,498 | 181,727 | ||||||
| Long-term debt, excluding current portion |
2,000,548 | 1,999,026 | ||||||
| Deferred income tax liabilities |
399,129 | 436,263 | ||||||
| Tax receivable agreement obligations to related parties |
155,264 | 150,496 | ||||||
| Other long-term liabilities |
13,333 | 11,824 | ||||||
| Commitments and contingencies |
||||||||
| Equity: |
||||||||
| Common stock (par value, $.01), 100 shares authorized and outstanding at June 30, 2014 and December 31, 2013, respectively |
— | — | ||||||
| Additional paid-in capital |
1,144,280 | 1,139,375 | ||||||
| Accumulated other comprehensive income (loss) |
(2,175 | ) | (1,343 | ) | ||||
| Accumulated deficit |
(232,002 | ) | (169,486 | ) | ||||
|
|
|
|
|
|||||
| Total equity |
910,103 | 968,546 | ||||||
|
|
|
|
|
|||||
| Total liabilities and equity |
$ | 3,647,875 | $ | 3,747,882 | ||||
|
|
|
|
|
|||||
4
Emdeon Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited and amounts in thousands)
| Six Months | Six Months | |||||||
| Ended June 30, | Ended June 30, | |||||||
| 2014 | 2013 | |||||||
| Operating activities |
||||||||
| Net income (loss) |
$ | (62,516 | ) | $ | (41,720 | ) | ||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||||||
| Depreciation and amortization |
93,093 | 90,762 | ||||||
| Accretion |
4,768 | 11,599 | ||||||
| Equity compensation |
3,682 | 3,547 | ||||||
| Deferred income tax expense (benefit) |
(48,695 | ) | (27,451 | ) | ||||
| Amortization of debt discount and issuance costs |
3,843 | 4,717 | ||||||
| Contingent consideration |
1,670 | — | ||||||
| Loss on extinguishment of debt |
— | 22,828 | ||||||
| Impairment of long-lived assets |
79,576 | 1,862 | ||||||
| Other |
(2,029 | ) | — | |||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
(25,648 | ) | (10,208 | ) | ||||
| Prepaid expenses and other |
(7,251 | ) | (697 | ) | ||||
| Accounts payable |
1,237 | 5,498 | ||||||
| Accrued expenses, deferred revenue and other liabilities |
(7,897 | ) | 23,539 | |||||
| Tax receivable agreement obligations to related parties |
— | (104 | ) | |||||
|
|
|
|
|
|||||
| Net cash provided by (used in) operating activities |
33,833 | 84,172 | ||||||
|
|
|
|
|
|||||
| Investing activities |
||||||||
| Purchases of property and equipment |
(25,952 | ) | (33,246 | ) | ||||
| Payments for acquisitions, net of cash acquired |
(779 | ) | (18,291 | ) | ||||
| Proceeds from sale of cost method investment |
36 | — | ||||||
|
|
|
|
|
|||||
| Net cash provided by (used in) investing activities |
(26,695 | ) | (51,537 | ) | ||||
|
|
|
|
|
|||||
| Financing activities |
||||||||
| Debt principal payments |
(7,669 | ) | (6,472 | ) | ||||
| Payment of debt assumed from acquisition |
(1,877 | ) | — | |||||
| Payment of loan costs |
— | (2,178 | ) | |||||
| Repayment of deferred financing arrangements |
(4,176 | ) | (1,844 | ) | ||||
| Repurchase of Parent common stock |
(869 | ) | (250 | ) | ||||
| Capital contribution from Parent |
2,092 | — | ||||||
| Other |
— | (735 | ) | |||||
|
|
|
|
|
|||||
| Net cash provided by (used in) financing activities |
(12,499 | ) | (11,479 | ) | ||||
|
|
|
|
|
|||||
| Net increase (decrease) in cash and cash equivalents |
(5,361 | ) | 21,156 | |||||
| Cash and cash equivalents at beginning of period |
76,538 | 31,763 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ | 71,177 | $ | 52,919 | ||||
|
|
|
|
|
|||||
5
Explanation of Non-GAAP Financial Measures
Emdeon’s management believes that, in order to properly understand Emdeon’s short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.
In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income before net interest expense, income tax provision (benefit) and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, “EBITDA Adjustments”).
To properly evaluate Emdeon’s business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeon’s business. Emdeon also strongly encourages investors to review the reconciliation of net income (loss) to the non-GAAP measure of Adjusted EBITDA. Adjusted EBITDA, as Emdeon defines it, may differ from and may not be comparable to similarly titled measures used by other companies, because Adjusted EBITDA is not a measure of financial performance under GAAP and is susceptible to varying calculations. Adjusted EBITDA calculations are also used in our credit facilities and indentures, although the adjustments used to calculate Adjusted EBITDA as used in our credit facilities and indentures may vary in certain respects among such agreements and from those presented below.
Management uses Adjusted EBITDA to facilitate a comparison of Emdeon’s operating performance on a consistent basis from period to period that, when viewed in combination with Emdeon’s GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeon’s business than GAAP measures alone. Management believes this non-GAAP measure assists Emdeon’s board of directors, management, lenders and investors in comparing Emdeon’s operating performance on a consistent basis because it removes where applicable, the impact of Emdeon’s capital structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeon’s operating performance.
6
Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(unaudited and amounts in thousands)
| Three Months | Three Months | Six Months | Six Months | |||||||||||||
| Ended June 30, | Ended June 30, | Ended June 30, | Ended June 30, | |||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Net income (loss) |
$ | (59,527 | ) | $ | (28,268 | ) | $ | (62,516 | ) | $ | (41,720 | ) | ||||
| Interest expense, net |
36,543 | 37,974 | 73,106 | 79,389 | ||||||||||||
| Income tax provision (benefit) |
(26,959 | ) | (17,191 | ) | (48,226 | ) | (26,547 | ) | ||||||||
| Depreciation and amortization |
46,630 | 43,946 | 93,093 | 90,762 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA |
(3,313 | ) | 36,461 | 55,457 | 101,884 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA Adjustments: |
||||||||||||||||
| Equity compensation |
1,790 | 1,773 | 3,682 | 3,547 | ||||||||||||
| Acquisition accounting adjustments |
225 | 216 | 477 | 490 | ||||||||||||
| Acquisition-related costs |
2,114 | 609 | 3,521 | 1,260 | ||||||||||||
| Transaction-related costs and advisory fees |
1,615 | 1,825 | 3,115 | 3,325 | ||||||||||||
| Strategic initiatives, duplicative and transition costs |
4,715 | 1,055 | 9,808 | 2,468 | ||||||||||||
| Severance and retention costs |
1,051 | 744 | 3,979 | 1,629 | ||||||||||||
| Loss on extinguishment of debt and other related costs |
— | 24,311 | — | 24,311 | ||||||||||||
| Accretion expense |
4,844 | 7,459 | 4,768 | 11,599 | ||||||||||||
| Impairment of long-lived assets |
76,508 | 1,893 | 79,576 | 1,862 | ||||||||||||
| Contingent consideration |
(290 | ) | — | 1,670 | — | |||||||||||
| Other non-routine |
1,071 | 806 | 2,582 | 820 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA Adjustments |
93,643 | 40,691 | 113,178 | 51,311 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | 90,330 | $ | 77,152 | $ | 168,635 | $ | 153,195 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
7